Editing the Epigenome in Neurodegenerative Diseases

—Targeted genome editing using the CRISPR/Cas9 system, which was introduced into practice in recent years and has become one of the most impressive achievements in modern molecular biology, makes it possible to efficiently correct genetic information at the cellular level. For therapeutic purposes,...

Full description

Saved in:
Bibliographic Details
Published in:Neurochemical journal 2021-10, Vol.15 (4), p.359-366
Main Authors: Vetchinova, A. S., Fedotova, E. Yu, Illarioshkin, S. N.
Format: Article
Language:English
Subjects:
Biomedical and Life Sciences
Biomedicine
Neurosciences
Review Articles
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:—Targeted genome editing using the CRISPR/Cas9 system, which was introduced into practice in recent years and has become one of the most impressive achievements in modern molecular biology, makes it possible to efficiently correct genetic information at the cellular level. For therapeutic purposes, it is important to make rapid and precise changes in the nucleotide sequence of the genome in vivo. While editing genes involves changing the DNA nucleotide sequence itself and direct correction of genetic information, epigenetic editing is aimed at controlling the expression of certain genes, primarily by changing the methylation status of specified sites in the genome. Thus, by editing epigenomic parameters, researchers can determine the exact biological role of epigenetic modification in the development of a particular pathology. The review presents the fundamental and technological foundations of epigenomic editing, as well as the current abilities of this advanced technology in the study of neurodegenerative diseases.
ISSN:1819-7124
1819-7132
DOI:10.1134/S1819712421040152